TxCell names new CEO
This article was originally published in Scrip
Biotechnology company TxCell, which develops personalized cell-based immunotherapies using for chronic inflammatory and autoimmune diseases, has named Damian Marron chief executive officer. Prior to joining the Valbonne, France-based firm, Mr Marron was CEO of clinical stage biotechnology company Cytheris. Furthermore, from 2008-2012 he was CEO of Trophos. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases. Mr Marron succeeds Francois Meyer who has now been appointed executive chair of the TxCell's board of directors.